622 related articles for article (PubMed ID: 11556839)
1. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
2. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
3. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
4. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
5. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
6. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
10. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
12. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
14. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
[TBL] [Abstract][Full Text] [Related]
15. Minimal breast cancer: evaluation of histology and biological marker expression.
Dublin EA; Millis RR; Smith P; Bobrow LG
Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
17. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
[TBL] [Abstract][Full Text] [Related]
18. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
19. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]